Drugs / GSK Biologicals' reduced-antigen-content acellular pertussis vaccine
GSK Biologicals' reduced-antigen-content acellular pertussis vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01262924 | Oct 1997 → Dec 1998 | — | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK Biologicals' reduced-antigen-content acellular pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01262924 ↗ |
| Modality | Vaccine | “GSK Biologicals' reduced-antigen-content acellular pertussis vaccine” NCT01262924 ↗ |
| Route | Intramuscular | “Intramuscular, single dose” NCT01262924 ↗ |